Immunome, Inc. (IMNM)

Over the past six months, Immunome's stock price has been impacted by several events. Positive Phase 3 results for Varegacestat led to a significant surge in the stock price. The company announced and priced a public offering of common stock. Immunome presented at investor conferences, including the Guggenheim Emerging Outlook: Biotech Summit 2026 and the 44th Annual J.P. Morgan Healthcare Conference. The company reported inducement grants under Nasdaq Listing Rule 5635(c)(4). The stock has surged over 143% in the past year, with analyst consensus price targets being raised.

Analysis of Immunome Inc. (IMNM) stock suggests a seasonal timeframe of strength from June 20 to September 30, which has historically resulted in a geometric average return of 42.97% above the S&P 500 Total Return Index over the past four years. This seasonal pattern aligns with the broader Healthcare sector's period of seasonal strength, which typically runs from April 25 to December 4. However, this seasonal analysis is based on only four years of data for IMNM, which may be insufficient to create a fully reliable seasonal profile.

Immunome, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted cancer therapies. The company's portfolio includes antibody-drug conjugates (ADCs), radioligand therapies, and small molecules. Its most advanced programs include Varegacestat, a gamma secretase inhibitor in Phase 3 for desmoid tumors; IM-1021, a ROR1-targeted ADC in Phase 1 for B-cell lymphomas and solid tumors; and IM-3050, a FAP-targeted radioligand therapy expected to enter Phase 1 in early 2026. The company also has a preclinical pipeline of ADCs targeting undisclosed solid tumors.

Immunome, Inc. is headquartered in Bothell, Washington, USA, and was originally founded in Exton, Pennsylvania, USA.

Immunome, Inc. generally holds a positive brand reputation, particularly within the investment community. The company has a consensus rating of "Moderate Buy" from analysts. MarketBeat scored Immunome higher than 66% of evaluated companies in the medical sector. This positive sentiment is driven by investor confidence in its clinical pipeline, especially following the promising Phase 3 results for varegacestat. The company's leadership also contributes to its reputation.

The ownership structure of Immunome stock includes institutional, retail, and individual investors. Approximately 32.15% of the company's stock is owned by Institutional Investors, 4.91% by Insiders, and 62.94% by Public Companies and Individual Investors. Major institutional shareholders include Fmr Llc, T. Rowe Price Investment Management, Inc., Vanguard Group Inc., and BlackRock, Inc. Insiders, including Isaac Barchas, Clay B. Siegall, and others, also hold company stock.